Vaxcyte, Inc. (PCVX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $48.63: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 8.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum.
Vaxcyte is a clinical-stage vaccine company developing broad-spectrum pneumococcal conjugate vaccines (PCVs) using its XpressCF cell-free protein synthesis platform. It has no product revenue; the company had a net loss of $766.6M in 2025 and an accumulated deficit of $2.2B,... Read more
Sell if holding. Engine safety override at $48.63: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 8.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.0/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Vaxcyte, Inc.
Latest news
- Earnings Scheduled For May 6, 2026 — benzinga May 6, 2026 neutral
- Vaxcyte Q1 EPS $(2.30) Misses $(1.82) Estimate — benzinga May 6, 2026 negative
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineVAX-31 PCV franchise10-K Item 1A: 'Our business and future success depends on our ability to successfully develop, obtain regulatory approval of, and then commercialize our PCV candidates, which include VAX-31, our 31-valent clinical PCV candidate'
- HIGHSupplierLonza10-K Item 1: 'We have access to substantial manufacturing resources through our contract manufacturer, Lonza, that we believe can facilitate an independent path to market.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $48.63: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 8.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $46.21. Score 5.0/10, moderate confidence.
Take-profit target: $94.83 (+95.0% upside). Prior stop was $46.21. Stop-loss: $46.21.
Concentration risk — Pipeline: VAX-31 PCV franchise; Concentration risk — Supplier: Lonza; Quality below floor (1.2 < 4.0).
Vaxcyte, Inc. trades at a P/E of N/A (forward -6.5). TrendMatrix value score: 9.0/10. Verdict: Sell.
17 analysts cover PCVX with a consensus score of 4.3/5. Average price target: $109.
What does Vaxcyte, Inc. do?Vaxcyte is a clinical-stage vaccine company developing broad-spectrum pneumococcal conjugate vaccines (PCVs) using its...
Vaxcyte is a clinical-stage vaccine company developing broad-spectrum pneumococcal conjugate vaccines (PCVs) using its XpressCF cell-free protein synthesis platform. It has no product revenue; the company had a net loss of $766.6M in 2025 and an accumulated deficit of $2.2B, funded by $2.4B in cash and investments as of December 31, 2025.